Roche Holding AG
CHF 311.40
+ CHF2.85 (0.92%)
CHF 311.40
+ CHF2.85 (0.92%)
End-of-day quote: 11/25/2022

Roche Holding Stock

About Roche Holding

Roche Holding AG engages in diagnostics and pharmaceuticals businesses in Switzerland, Germany, and rest of Europe. The company focuses on finding new medicines and diagnostics that help patients live longer, better lives and evolve the practice of medicine.

The company offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, liver, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus diseases.


In 2017, the company acquired a 100% controlling interest in mySugr GmbH, which has developed one of the leading mobile diabetes platforms in the market. Viewics is a software company focused on laboratory business analytics.

In 2017 the company announced an agreement to fully acquire Ignyta, Inc. with a total transaction.

Significant Events Roche Holding share price history

In September 2022, Roche Holding AG announced a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD).

In March 2021, Roche Holding AG announced the signing of a multi-year research collaboration and licensing agreement with SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases.

In August 2020, Carrick Therapeutics, announced a clinical collaboration with Roche to evaluate a novel combination of Carrick’s samuraciclib and Roche’s giredestrant in CDK4/6i resistant HR+, HER2- metastatic breast cancer. The collaboration will utilize Roche’s MORPHEUS Phase 1b/2 platform for rapid and efficient combination development, with upfront randomization versus a control group.


Roche Holding AG was founded in 1896.

IPO Date:
ISIN Number:

Contact Details

Konzern Hauptsitz, Grenzacherstrasse 124, Basel, Basel-Stadt, 4070, Switzerland
Phone Number
41 61 688 11 11

Key Executives

Schwan, Severin
Hippe, Alan
Data Unavailable

© Copyright 2022 | TopGraphs™ | All Rights Reserved

To use TopGraphs™, you must accept our Terms and Conditions and Privacy Policy